Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 333

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma

Open access
Gross, Neil D., Miller, David M., Khushalani, Nikhil I., Divi, Vasu, Ruiz, Emily S., Lipson, Evan J., Meier, Friedegund, Su, Yungpo B., Swiecicki, Paul L., Atlas, Jennifer, Geiger, Jessica L., Hauschild, Axel, Choe, Jennifer H., Hughes, Brett G.M., Schadendorf, Dirk, Patel, Vishal A., Homsi, Jade, Taube, Janis M., Lim, Annette M., Ferrarotto, Renata, Kaufman, Howard L., Seebach, Frank, Lowy, Israel, Yoo, Suk-Young, Mathias, Melissa, Fenech, Keilah, Han, Hyunsil, Fury, Matthew G., Rischin, Danny·2022·New England Journal of Medicine

Abstract

BACKGROUND: In a pilot study involving patients with cutaneous squamous-cell carcinoma, a high percentage of patients had a pathological complete response with the use of two doses of neoadjuvant cemiplimab before surgery. Data from a phase 2 study are needed to confirm these findings. METHODS: We conducted a phase 2, confirmatory, multicenter, nonrandomized study to evaluate cemiplimab as neoadjuvant therapy in patients with resectable stage II, III, or IV (M0) cutaneous squamous-cell carcinoma. Patients received cemiplimab, administered at a dose of 350 mg every 3 weeks for up to four doses, before undergoing surgery with curative intent. The primary end point was a pathological complete response (the absence of viable tumor cells in the surgical specimen) on independent review at a central laboratory, with a null hypothesis that a pathological complete response would be observed in 25% of patients. Key secondary end points included a pathological major response (the presence of viable tumor cells that constitute ≤10% of the surgical specimen) on independent review, a pathological complete response and a pathological major response on investigator assessment at a local laboratory, an objective response on imaging, and adverse events. RESULTS: A total of 79 patients were enrolled and received neoadjuvant cemiplimab. On independent review, a pathological complete response was observed in 40 patients (51%; 95% confidence interval [CI], 39 to 62) and a pathological major response in 10 patients (13%; 95% CI, 6 to 22). These results were consistent with the pathological responses determined on investigator assessment. An objective response on imaging was observed in 54 patients (68%; 95% CI, 57 to 78). Adverse events of any grade that occurred during the study period, regardless of whether they were attributed to the study treatment, were observed in 69 patients (87%). Grade 3 or higher adverse events that occurred during the study period were observed in 14 patients (18%). CONCLUSIONS: Neoadjuvant therapy with cemiplimab was associated with a pathological complete response in a high percentage of patients with resectable cutaneous squamous-cell carcinoma. (Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov number, NCT04154943.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2209813

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 333

Metadata

Authors
Gross, N. D., Miller, D. M., Khushalani, N. I., Divi, V., Ruiz, E. S., Lipson, E. J., Meier, F., Su, Y. B., Swiecicki, P. L., Atlas, J., Geiger, J. L., Hauschild, A., Choe, J. H., Hughes, B. G. M., Schadendorf, D., Patel, V. A., Homsi, J., Taube, J. M., Lim, A. M., Ferrarotto, R., Kaufman, H. L., Seebach, F., Lowy, I., Yoo, S.-Y., Mathias, M., Fenech, K., Han, H., Fury, M. G., & Rischin, D.
Venue
New England Journal of Medicine
Published
2022-10-27
Volume
387
Issue
17
Pages
1557-1568
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4295271013
Cited by
333
References
16
FWCI
41.64
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. https://app.cochat.ai/papers/10.1056/nejmoa2209813
The paper
Gross, N. D., Miller, D. M., Khushalani, N. I., Divi, V., Ruiz, E. S., Lipson, E. J., Meier, F., Su, Y. B., Swiecicki, P. L., Atlas, J., Geiger, J. L., Hauschild, A., Choe, J. H., Hughes, B. G. M., Schadendorf, D., Patel, V. A., Homsi, J., Taube, J. M., Lim, A. M., . . . Rischin, D. (2022). Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2209813

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.